Brentuximab Vedotin

Last Updated: 09/19/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1868 publications

Hypereosinophilic syndrome and suspected myeloid neoplasia in relapsed Hodgkin lymphoma during immune checkpoint inhibitor therapy: a rare case.

Hypereosinophilic syndrome and suspected myeloid neoplasia in relapsed Hodgkin lymphoma during immune checkpoint inhibitor therapy: a rare case.

Journal: Leukemia & lymphoma

Published: August 30, 2026

Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein-Barr virus-positive classic Hodgkin lymphoma with rituximab.

Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein-Barr virus-positive classic Hodgkin lymphoma with rituximab.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: August 30, 2026

Incidence of clinically significant chemotherapy induced nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis.

Incidence of clinically significant chemotherapy induced nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis.

Journal: Leukemia & lymphoma

Published: August 24, 2026

Clinical study of brentuximab vedotin combined with the ifosfamide and gemcitabine regimen in the treatment of children with relapsed or refractory classic Hodgkin lymphoma

Clinical study of brentuximab vedotin combined with the ifosfamide and gemcitabine regimen in the treatment of children with relapsed or refractory classic Hodgkin lymphoma

Journal: Zhonghua er ke za zhi = Chinese journal of pediatrics

Published: August 17, 2026

Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma.

Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma.

Journal: JCO oncology advances

Published: August 11, 2026

Classic Hodgkin Lymphoma: A Review.

Classic Hodgkin Lymphoma: A Review.

Journal: JAMA

Published: August 03, 2026

Successful treatment of CD30-positive nodal follicular helper T-cell lymphoma, follicular type, with A-CHP and tucidinostat

Successful treatment of CD30-positive nodal follicular helper T-cell lymphoma, follicular type, with A-CHP and tucidinostat

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 03, 2026

Recent advances and future perspectives in the treatment of classical Hodgkin lymphoma

Recent advances and future perspectives in the treatment of classical Hodgkin lymphoma

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 03, 2026

Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group.

Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: July 30, 2026

Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO) Support in Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma With Pulmonary Involvement at Presentation.

Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO) Support in Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma With Pulmonary Involvement at Presentation.

Journal: Cureus

Published: July 30, 2026

Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.

Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.

Journal: Hematology (Amsterdam, Netherlands)

Published: July 11, 2026

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Journal: Future oncology (London, England)

Published: July 06, 2026

Showing 1-12 of 1,868

Last Updated: 09/19/2026